NYXOAH S A Stock Price, News & Analysis

Nyxoah (NASDAQ:NYXH) announced the publication of its DREAM pivotal study data in the Journal of Clinical Sleep Medicine, showcasing comprehensive 12-month safety and efficacy results for its Genio® system in treating Obstructive Sleep Apnea (OSA).

The study demonstrated strong results with 63.5% AHI responder rate and 71.3% ODI responder rate. Patient engagement was remarkable, with 84.3% of participants using the device more than 4 hours in over 70% of nights, and 90% of patients expressing satisfaction. The device showed a 66.6% median reduction in supine AHI at 12 months.

Safety results aligned with other neuromodulation therapies, showing 11 serious adverse events in ten subjects (8.7% SAE rate), with only three being device-related. Quality-of-life outcomes improved significantly, with a 2.3-point increase in FOSQ assessment and 3.4-point reduction in Epworth Sleepiness Score.

Nyxoah (NASDAQ/Euronext: NYXH) has disclosed its updated share capital and voting rights information as of June 27, 2025. The company's share capital stands at EUR 6,431,121.38 with a total of 37,435,640 ordinary shares, each carrying one voting right. Additionally, there are 2,822,816 subscription rights not yet issued, excluding 478,057 subscription rights that were issued but not yet granted.

Nyxoah SA (NYXH) has announced an extraordinary shareholders' meeting scheduled for July 2, 2025, at 2:00 p.m. CET at the company's headquarters. The key agenda item involves amending Article 13 of the company's articles of association to introduce new director nomination rights for stable shareholders. Under the proposed change, shareholders holding at least 5% of outstanding shares continuously for 3 years will gain the right to nominate one director. This right is limited to the two largest stable shareholders. The meeting will be accessible both in-person and via video conference, though remote participants must vote by mail or proxy before June 26, 2025. The registration date is set for June 18, 2025, and shareholders must confirm their participation by June 26, 2025.

Nyxoah SA announced receiving a transparency notification from Vestal Point Capital regarding changes in voting rights holdings. According to the notification dated May 27, 2025, Vestal Point Capital reduced its position to 1,809,843 voting rights, representing 4.84% of total voting rights (37,427,265) as of May 21, 2025. This represents a significant decrease from their previous holding of 3,000,688 voting rights. Vestal Point Capital, LP is controlled by Vestal Point Capital, LLC as general partner, which is in turn controlled by Ryan Wilder as managing member. The notification was triggered by crossing below the 5% threshold.

Nyxoah SA (NYXH), a medical technology company focused on developing innovative treatments for Obstructive Sleep Apnea (OSA), has announced its participation in the upcoming Jefferies Global Healthcare Conference in New York from June 3-5, 2025. CEO Olivier Taelman will deliver a corporate presentation on June 4, 2025, at 4:55pm ET. The presentation will be accessible via webcast on Nyxoah's Investor Relations website's Events section. The company will also be available for one-on-one meetings with institutional investors during the conference.

Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released an update on its share capital and voting rights structure as of May 23, 2025. The company's share capital stands at EUR 6,430,026.16. The total number of securities carrying voting rights is 37,429,265 ordinary shares, with an equal number of voting rights. Additionally, there are 2,854,068 subscription rights to securities not yet issued, excluding 478,057 subscription rights that were issued but not yet granted.

Nyxoah reported its Q1 2025 financial results and provided an update on its FDA approval progress for the Genio® system, a neuromodulation treatment for Obstructive Sleep Apnea (OSA). The company received an FDA Approvable Letter and successfully completed validation requirements, with only the final site inspection pending. Q1 2025 financial highlights include: - Revenue of €1.1M (down from €1.2M in Q1 2024) - Operating loss increased to €20.6M (vs €12.2M in Q1 2024) - Cash position of €63.0M as of March 31, 2025 - Gross margin of 61.8% The company expects potential FDA approval in Q2 2025, having already completed most regulatory requirements. The increased operating loss reflects higher R&D expenses (€9.0M) and selling, general and administrative costs (€12.4M) as Nyxoah prepares for U.S. commercialization.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has received a transparency notification from FMR LLC regarding changes in shareholding. FMR LLC and its controlled undertakings now hold 1,111,240 voting rights (2.97% of total voting rights) as of April 29, 2025, consisting of 987,776 voting rights linked to securities and 123,464 equivalent financial instruments. This represents a downward crossing below the 3% threshold.

The voting rights are distributed among Fidelity Management & Research Company LLC (2.07%), FIAM LLC (0.00%), and FMR Investment Management UK Limited (0.57%). The notification includes a stock loan as an equivalent financial instrument representing 0.33% of voting rights.

Nyxoah SA (NYXH) has announced its annual and extraordinary shareholders' meetings to be held on June 11, 2025, at 2:00 p.m. CET. The meetings will take place at the company's headquarters in Mont-Saint-Guibert, Belgium. Key agenda items include: Annual Meeting Highlights: - Review and approval of 2024 financial statements - Discharge of directors and statutory auditor - Approval of amended remuneration policy - Authorization for increased severance packages for CEO and CFO (up to 18 months) in case of change of control - Reappointment of multiple directors including Robelga SRL, Jürgen Hambrecht, and Kevin Rakin - Reappointment of Ernst & Young as statutory auditor Extraordinary Meeting: - Proposed amendment to Article 13 of articles of association regarding director nomination rights for shareholders holding ≥5% of shares for 3+ years